EUROEYES INTERNATIONAL EYE CLINIC LIMITED Financials EuroEyes International Eye Clinic Limited
Equities
1846
KYG3224D1088
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.95 HKD | +3.12% |
|
+5.54% | -4.99% |
| 04-26 | EuroEyes International to Buy Back Up to 3% Shares | MT |
| 04-24 | EuroEyes International Logs 6% Growth in Q1 Eye Surgeries | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,759 | 2,878 | 2,693 | 1,829 | 1,650 | 1,650 | - |
| Enterprise Value (EV) 1 | 2,759 | 2,878 | 2,693 | 1,829 | 1,736 | 1,650 | 1,650 |
| P/E ratio | -652 x | 50.1 x | 20.2 x | 20.4 x | 13.2 x | 8.25 x | - |
| Yield | - | - | 1.21% | 1.14% | 2.22% | 2.83% | - |
| Capitalization / Revenue | 6.71 x | 6.07 x | 4.26 x | 3 x | 2.43 x | 1.89 x | 1.63 x |
| EV / Revenue | 6.71 x | 6.07 x | 4.26 x | 3 x | 2.43 x | 1.89 x | 1.63 x |
| EV / EBITDA | 21.3 x | 15.2 x | 10.1 x | 8.57 x | 6.18 x | 4.91 x | 3.55 x |
| EV / FCF | 86.1 x | 71.7 x | - | 23.8 x | 14.4 x | 9.14 x | 8.98 x |
| FCF Yield | 1.16% | 1.39% | - | 4.21% | 6.95% | 10.9% | 11.1% |
| Price to Book | 2.77 x | 3.02 x | 2.67 x | 1.8 x | 1.43 x | 1.25 x | - |
| Nbr of stocks (in thousands) | 329,234 | 329,234 | 329,234 | 333,240 | 333,240 | 333,240 | - |
| Reference price 2 | 8.380 | 8.740 | 8.180 | 5.490 | 4.950 | 4.950 | 4.950 |
| Announcement Date | 25/03/20 | 16/03/21 | 23/03/22 | 28/03/23 | 28/03/24 | - | - |
1HKD in Million2HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 368.7 | 411.4 | 473.8 | 632.9 | 610.3 | 714.3 | 874 | 1,009 |
| EBITDA 1 | - | 129.7 | 189.2 | 265.9 | 213.5 | 280.9 | 336 | 464.7 |
| EBIT 1 | - | 29.13 | 107.6 | 189.8 | 132.8 | 193.5 | 291 | 306.9 |
| Operating Margin | - | 7.08% | 22.7% | 29.99% | 21.76% | 27.09% | 33.3% | 30.4% |
| Earnings before Tax (EBT) 1 | - | 20.41 | 98.65 | 195.7 | 129 | 190.6 | 282 | 297.7 |
| Net income 1 | - | -3.293 | 65.58 | 133.6 | 89.47 | 131.2 | 201 | 218.9 |
| Net margin | - | -0.8% | 13.84% | 21.1% | 14.66% | 18.37% | 23% | 21.69% |
| EPS 2 | - | -0.0128 | 0.1746 | 0.4058 | 0.2693 | 0.3950 | 0.6000 | - |
| Free Cash Flow 1 | - | 32.03 | 40.12 | - | 76.95 | 114.6 | 180.4 | 183.7 |
| FCF margin | - | 7.79% | 8.47% | - | 12.61% | 15.42% | 20.64% | 18.2% |
| FCF Conversion (EBITDA) | - | 24.7% | 21.2% | - | 36.04% | 37.39% | 53.69% | 39.53% |
| FCF Conversion (Net income) | - | - | 61.17% | - | 86.01% | 72.37% | 89.75% | 83.92% |
| Dividend per Share 2 | - | - | - | 0.0993 | 0.0627 | 0.1100 | 0.1400 | - |
| Announcement Date | 29/09/19 | 25/03/20 | 16/03/21 | 23/03/22 | 28/03/23 | 28/03/24 | - | - |
1HKD in Million2HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | 32 | 40.1 | - | 77 | 115 | 180 | 184 |
| ROE (net income / shareholders' equity) | - | 9.78% | 8.19% | 14.1% | 8.86% | 17.3% | 21.6% | 14.9% |
| ROA (Net income/ Total Assets) | - | 5.55% | 5.66% | 9.96% | 6.15% | 9.9% | 12.1% | 11.1% |
| Assets 1 | - | -59.33 | 1,159 | 1,342 | 1,455 | 1,599 | 1,661 | 1,972 |
| Book Value Per Share 2 | - | 3.030 | 2.900 | 3.060 | 3.040 | 3.460 | 3.950 | - |
| Cash Flow per Share 2 | - | - | 0.2100 | 0.8300 | 0.6300 | 0.2200 | 0.7200 | - |
| Capex 1 | - | 27.9 | 38.3 | 44 | 56.3 | 98.3 | 131 | 76.1 |
| Capex / Sales | - | 6.79% | 8.09% | 6.95% | 9.23% | 13.22% | 14.95% | 7.54% |
| Announcement Date | 29/09/19 | 25/03/20 | 16/03/21 | 23/03/22 | 28/03/23 | 28/03/24 | - | - |
1HKD in Million2HKD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.95
HKD
Average target price
7.26
HKD
Spread / Average Target
+46.67%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.99% | 211M | |
| -21.25% | 2.91B | |
| -20.94% | 2.67B | |
| -60.16% | 2.06B | |
| -25.10% | 323M | |
| -47.38% | 172M | |
| -27.37% | 123M |
- Stock Market
- Equities
- 1846 Stock
- Financials EuroEyes International Eye Clinic Limited
